- Home
- BCRX vs ETNB Comparison
BCRX vs ETNB Comparison
Compare BCRX & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- ETNB
- Stock Information
- Founded
- BCRX 1986
- ETNB 2018
- Country
- BCRX United States
- ETNB United States
- Employees
- BCRX N/A
- ETNB N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- ETNB Health Care
- Exchange
- BCRX Nasdaq
- ETNB Nasdaq
- Market Cap
- BCRX 1.8B
- ETNB 1.5B
- IPO Year
- BCRX 1994
- ETNB 2019
- Fundamental
- Price
- BCRX $7.96
- ETNB $14.96
- Analyst Decision
- BCRX Strong Buy
- ETNB Strong Buy
- Analyst Count
- BCRX 10
- ETNB 10
- Target Price
- BCRX $16.70
- ETNB $27.22
- AVG Volume (30 Days)
- BCRX 2.3M
- ETNB 5.5M
- Earning Date
- BCRX 11-03-2025
- ETNB 11-06-2025
- Dividend Yield
- BCRX N/A
- ETNB N/A
- EPS Growth
- BCRX N/A
- ETNB N/A
- EPS
- BCRX N/A
- ETNB N/A
- Revenue
- BCRX $557,506,000.00
- ETNB N/A
- Revenue This Year
- BCRX $41.34
- ETNB N/A
- Revenue Next Year
- BCRX $6.11
- ETNB N/A
- P/E Ratio
- BCRX N/A
- ETNB N/A
- Revenue Growth
- BCRX 45.85
- ETNB N/A
- 52 Week Low
- BCRX $6.02
- ETNB $4.16
- 52 Week High
- BCRX $11.31
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- BCRX 42.41
- ETNB 82.21
- Support Level
- BCRX $7.64
- ETNB $7.84
- Resistance Level
- BCRX $7.99
- ETNB $9.47
- Average True Range (ATR)
- BCRX 0.22
- ETNB 0.44
- MACD
- BCRX -0.03
- ETNB 0.37
- Stochastic Oscillator
- BCRX 37.65
- ETNB 98.62
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).